Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation

被引:23
作者
Bobbink, IWG [1 ]
Tekelenburg, WLH [1 ]
Sixma, JJ [1 ]
deBoer, HC [1 ]
Banga, JD [1 ]
deGroot, PG [1 ]
机构
[1] UNIV UTRECHT HOSP,DEPT INTERNAL MED,NL-3508 GA UTRECHT,NETHERLANDS
关键词
D O I
10.1006/bbrc.1997.7718
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Plasminogen activation by tissue-plasminogen activator (t-PA) is accelerated by the presence of a macromolecular surface, which acts as a template that brings enzyme and substrate in close proximity. Modification of lysine residues, which are important for this template function, occurs in diabetic patients as a consequence of glycation of proteins. In this study, we investigated the effects of glycation of fibrin and other proteins in t-PA-catalyzed plasmin formation. Plasminogen activation on glycated fibrin(ogen) was increased compared to non-glycated fibrin(ogen), which could fully be attributed to an increased affinity of t-PA for glycated fibrin(ogen). Binding of plasminogen to glycated fibrin was increased, but did not contribute to increased plasminogen activation. Both plasminogen activator inhibitor-1 (PAI-1) binding and activity were increased on glycated fibrin. Induction of template function in plasminogen activation was also observed on immobilized glycated bovine serum albumin (BSA) and human gamma-globulins (IgG). Increased plasmin generation at sites of deposition of glycated proteins may lead to increased extracellular matrix breakdown and thereby affect the integrity of the endothelial monolayer. Moreover, soluble glycated BSA and glycated IgG call inhibit t-PA binding to immobilized glycated fibrin and interfere with fibrinolysis in diabetic patients. (C) 1997 Academic Press.
引用
收藏
页码:595 / 601
页数:7
相关论文
共 29 条
[1]
OVERVIEW ON FIBRINOLYSIS - PLASMINOGEN ACTIVATION PATHWAYS ON FIBRIN AND CELL-SURFACES [J].
ANGLESCANO, E .
CHEMISTRY AND PHYSICS OF LIPIDS, 1994, 67-8 :353-362
[2]
TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].
AUWERX, J ;
BOUILLON, R ;
COLLEN, D ;
GEBOERS, J .
ARTERIOSCLEROSIS, 1988, 8 (01) :68-72
[3]
ATHEROGENESIS IN DIABETES [J].
BIERMAN, EL .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (06) :647-656
[4]
BOBBINK WG, 1997, DIABETES, V46, P87
[5]
NON-ENZYMATIC GLYCOSYLATION REDUCES THE SUSCEPTIBILITY OF FIBRIN TO DEGRADATION BY PLASMIN [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
DIABETES, 1983, 32 (07) :680-684
[6]
INHIBITION OF HEPARIN-CATALYZED HUMAN ANTITHROMBIN III ACTIVITY BY NONENZYMATIC GLYCOSYLATION - POSSIBLE ROLE IN FIBRIN DEPOSITION IN DIABETES [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
DIABETES, 1984, 33 (06) :532-535
[7]
CHRISTE M, 1984, THROMB HAEMOSTASIS, V52, P138
[8]
CONFORTI G, 1994, BLOOD, V83, P994
[9]
PATHOPHYSIOLOGY OF DIABETIC-RETINOPATHY [J].
CUNHAVAZ, JG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1978, 62 (06) :351-355
[10]
BINDING OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR TO LYSINE, LYSINE ANALOGS, AND FIBRIN FRAGMENTS [J].
DEMUNK, GAW ;
CASPERS, MPM ;
CHANG, GTG ;
POUWELS, PH ;
ENGERVALK, BE ;
VERHEIJEN, JH .
BIOCHEMISTRY, 1989, 28 (18) :7318-7325